Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells
Authors:
- 29 July 2016
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 21 (10) , 1179-1190
Abstract
V-set and transmembrane domain-containing 1 (VSTM1), which is downregulated in bone marrow cells from leukemia patients, may provide a diagnostic and treatment target. Here, a triple-regulated oncolytic adenovirus was constructed to carry a VSTM1 gene expression cassette, SG611-VSTM1, and contained the E1a gene with a 24-nucleotide deletion within the CR2 region under control of the human telomerase reverse transcriptase promoter, E1b gene directed by the hypoxia response element, and VSTM1 gene controlled by the cytomegalovirus promoter. Real-time quantitative PCR and Western blot analyses showed that SG611-VSTM1 expressed VSTM1 highly efficiently in the human leukemic cell line K562 compared with SG611. In Cell Counting Kit-8 and flow cytometric assays, SG611-VSTM1 exhibited more potent anti-proliferative and pro-apoptotic effects in leukemic cells compared with SG611 and exerted synergistic cytotoxicity with low-dose daunorubicin (DNR) in vitro. In xenograft models, SG611-VSTM1 intratumorally injected at a dose of 1 × 109 plaque forming units combined with intraperitoneally injected low-dose DNR displayed significantly stronger antitumor effects than either treatment alone. Histopathologic examination revealed that SG611-VSTM1 induced apoptosis of leukemic cells. These results implicate an important role for VSTM1 in the pathogenesis of leukemia, and SG611-VSTM1 may be a promising agent for enhancing chemosensitivity in leukemia therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81570182)
- National Basic Research Program of China (2013CB733701)
- Specialized Research Fund for the Doctoral Program of Higher Education of China (20130001110079)
- Key Program of National Natural Science Foundation of China (81530046)
This publication has 35 references indexed in Scilit:
- VSTM-v1, a potential myeloid differentiation antigen that is downregulated in bone marrow cells from myeloid leukemia patientsJournal of Hematology & Oncology, 2015
- Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyOncotarget, 2015
- A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic CellsJournal of Immunotherapy, 2014
- Combination of adenoviruses expressing melanoma differentiation-associated gene-7 and chemotherapeutic agents produces enhanced cytotoxicity on esophageal carcinomaCancer Gene Therapy, 2014
- Preparation and Characterization of Monoclonal Antibodies Against VSTM1Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013
- VSTM1-v2, a novel soluble glycoprotein, promotes the differentiation and activation of Th17 cellsCellular Immunology, 2012
- Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 MoleculeCancer Research, 2012
- Combining conditionally replicating adenovirus‐mediated gene therapy with chemotherapy: A novel antitumor approachInternational Journal of Cancer, 2011
- Signal Inhibitory Receptor on Leukocytes-1 Is a Novel Functional Inhibitory Immune Receptor Expressed on Human PhagocytesThe Journal of Immunology, 2010
- Use of Replicating Oncolytic Adenoviruses in Combination Therapy for CancerClinical Cancer Research, 2004